Opiant Pharmaceuticals with ticker code (OPNT) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 44 and 38 with a mean TP of 41.33. Now with the previous closing price of 8.04 this indicates there is a potential upside of 414.1%. The 50 day MA is 8.08 while the 200 day moving average is 8.45. The company has a market cap of $34m. Company Website: http://www.opiant.com
Opiant Pharmaceuticals, a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for opioid overdose; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals in January 2016. Opiant Pharmaceuticals was founded in 2005 and is headquartered in Santa Monica, California.